Jane Poeschel, NP
Nurse Practitioner · Durand, WINPI 1316907231
Payments from drug & device makers
Across 258 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$379
- Novo Nordisk$358
- AstraZeneca$308
- Lilly USA, LLC$299
- Boehringer Ingelheim$262
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,211100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,422 |
| Amgen | 22 | $379 |
| Novo Nordisk | 22 | $358 |
| AstraZeneca | 20 | $308 |
| Lilly USA, LLC | 20 | $299 |
| Boehringer Ingelheim | 16 | $262 |
| E.r. Squibb & Sons, L.L.C. | 11 | $180 |
| Johnson & Johnson | 11 | $168 |
| Pfizer | 8 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $110 |
| Astellas Pharma US Inc | 6 | $101 |
| Mylan Specialty L.p. | 6 | $89 |
| Exact Sciences | 5 | $75 |
| GSK | 3 | $50 |
| Grifols USA, LLC | 3 | $40 |
| Bayer | 3 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Abbott | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Viatris Specialty LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$4,223 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $92,977 |
| OzempicSemaglutide | 56 | $55,623 |
| TrulicityDulaglutide | 57 | $54,890 |
| EliquisApixaban | 69 | $45,842 |
| JardianceEmpagliflozin | 29 | $20,723 |
| XareltoRivaroxaban | 33 | $18,809 |
| LinzessLinaclotide | 28 | $18,008 |
| FarxigaDapagliflozin Propanediol | 24 | $17,031 |
| Xtampza ErOxycodone Myristate | 11 | $13,480 |
| Repatha SureclickEvolocumab | 21 | $12,450 |
| TradjentaLinagliptin | 15 | $11,568 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,963 |
| EprontiaTopiramate | 13 | $5,394 |
| TresibaInsulin Degludec | 14 | $5,068 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $4,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $299 | $147,867138 claims |
| Novo NordiskOzempic, Tresiba | $358 | $60,69170 claims |
| PfizerEliquis | $162 | $45,84269 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $262 | $42,25463 claims |
| AstraZenecaFarxiga, Symbicort | $308 | $20,81140 claims |
| AbbVieLinzess, Synthroid | $1,422 | $19,13757 claims |
| Johnson & JohnsonXarelto | $168 | $18,80933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Other nurse practitioner in Durand
- Cynthia CarlsonMadison$891K
- Jodi StrongStevens Point$246K
- Jo Ellen FrawleyPrairie du Sac$194K
- Trisha WilcoxMilwaukee$174K
- Sally BowaGreen Bay$117K
- Christina SauldMilwaukee$111K
- Melissa WendellWausau$98K
- Colleen TrevinoMilwaukee$94K
- Nicole BarteltWaukesha$85K
- Kari FisherPrairie du Sac$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.